0001213900-17-009834.txt : 20170919 0001213900-17-009834.hdr.sgml : 20170919 20170919163028 ACCESSION NUMBER: 0001213900-17-009834 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170919 DATE AS OF CHANGE: 20170919 EFFECTIVENESS DATE: 20170919 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellect Biotechnology Ltd. CENTRAL INDEX KEY: 0001671502 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-295025 FILM NUMBER: 171092293 BUSINESS ADDRESS: STREET 1: 23 HATA'AS STREET CITY: KFAR SABA STATE: L3 ZIP: 44425 BUSINESS PHONE: 97299741444 MAIL ADDRESS: STREET 1: 23 HATA'AS STREET CITY: KFAR SABA STATE: L3 ZIP: 44425 FORMER COMPANY: FORMER CONFORMED NAME: Cellect Biomed Ltd. DATE OF NAME CHANGE: 20160406 D 1 primary_doc.xml X0708 D LIVE 0001671502 Cellect Biotechnology Ltd. 23 HATA'AS STREET KFAR SABA L3 ISRAEL 41444 972 99741444 ISRAEL T.R.F. Capital Ltd. Cellect Biomed Ltd. Corporation true Kasbian Nuriel Chirich 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Shai Yarkoni 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Executive Officer Director Eyal Leibovitz 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Executive Officer Abraham Nahmias 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Ruth Ben Yakar 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Yuval Berman 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director David Grossman 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Michael Berelowitz 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Pharmaceuticals No Revenues 06b false 2017-09-11 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 CA CALIFORNIA CT CONNECTICUT NY NEW YORK true 4303000 4302202 798 The warrants and shares underlying the warrants, the subject matter of this Form D were issued in connection with an offering of (i) 531,136 ADSs issued in a registered direct offering, which are not subject to this Form D, and (ii) unregistered warrants false 18 84963 0 H.C. Wainwright, LLC is also entitled to non-accountable expense reimbursement of $15,000 and up to $30,000 for certain expenses. H.C. Wainwright is entitled to warrants to purchase an aggregate of 7,492 ADSs exercisable at $10.125 per ADS for five years. 0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers false Cellect Biotechnology Ltd. /s/ Eyal Leibovitz Eyal Leibovitz Chief Financial Officer 2017-09-19